BioMarin Pharmaceutical Inc. Stock News

BioMarin reported positive data for valoctocogene roxaparvovec in adults suffering from severe hemophilia A. Evolent loses Medicaid contract. Moderna begins dos

Avidity Biosciences has filed to raise $100 million in an IPO, although the final figure may differ. The firm is development treatments for various muscular dys

Their crimes include rape, firearm possession, death by dangerous driving, Class A drugs possession and burglary

Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases,

Revenue is climbing at these biotech companies. And one of them is waiting for what could be an historic product approval.

Revenue is climbing at these biotech companies. And one of them is waiting for what could be an historic product approval.

Global biotech BioMarin Pharmaceutical Inc. (BMRN) has announced updated results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults wi

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy

SAN RAFAEL, Calif., May 31, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocog

REGN vs. BMRN: Which Stock Is the Better Value Option?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

Hardening of positions comes after international outcry over China’s parliament voting to proceed with controversial national security laws